| Year |
Citation |
Score |
| 2023 |
Kuser-Abali G, Zhang Y, Szeto P, Zhao P, Masoumi-Moghaddam S, Fedele CG, Leece I, Huang C, Cheung JG, Ameratunga M, Noguchi F, Andrews MC, Wong NC, Schittenhelm RB, Shackleton M. UHRF1/UBE2L6/UBR4-mediated ubiquitination regulates EZH2 abundance and thereby melanocytic differentiation phenotypes in melanoma. Oncogene. PMID 36906655 DOI: 10.1038/s41388-023-02631-8 |
0.735 |
|
| 2022 |
Gangoda L, Schenk RL, Tai L, Szeto P, Cheung JG, Strasser A, Lessene G, Shackleton M, Herold MJ. Removal of BFL-1 sensitises some melanoma cells to killing by BH3 mimetic drugs. Cell Death & Disease. 13: 301. PMID 35379799 DOI: 10.1038/s41419-022-04776-y |
0.752 |
|
| 2021 |
Vergara IA, Mintoff CP, Sandhu S, McIntosh L, Young RJ, Wong SQ, Colebatch A, Cameron DL, Kwon JL, Wolfe R, Peng A, Ellul J, Dou X, Fedele C, Boyle S, ... ... Shackleton M, et al. Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling. Nature Communications. 12: 1434. PMID 33664264 DOI: 10.1038/s41467-021-21576-8 |
0.741 |
|
| 2020 |
Lynch FA, Katona L, Jefford M, Smith AB, Shaw J, Dhillon HM, Ellen S, Phipps-Nelson J, Lai-Kwon J, Milne D, Russell L, Dax V, Diggens J, Kent H, Button-Sloan A, ... ... Shackleton M, et al. Feasibility and Acceptability of : A Stepped-Care Program to Manage Fear of Cancer Recurrence in People with Metastatic Melanoma. Journal of Clinical Medicine. 9. PMID 32937942 DOI: 10.3390/Jcm9092969 |
0.328 |
|
| 2020 |
Samuel E, Lie G, Balasubramanian A, Hiong A, So Y, Voskoboynik M, Moore M, Shackleton M, Haydon A, John T, Mitchell PLR, Markman B, Briggs P, Parakh S. Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC. Clinical Lung Cancer. PMID 32778511 DOI: 10.1016/J.Cllc.2020.06.001 |
0.33 |
|
| 2020 |
Dall GV, Vieusseux J, Seyed-Razavi Y, Godde N, Ludford-Menting M, Russell SM, Ashworth A, Anderson RL, Risbridger GP, Shackleton M, Britt KL. Parity reduces mammary repopulating activity but does not affect mammary stem cells defined as CD24 + CD29/CD49fhi in mice. Breast Cancer Research and Treatment. PMID 32696317 DOI: 10.1007/S10549-020-05804-1 |
0.35 |
|
| 2020 |
Zhang X, Yang L, Szeto P, Abali GK, Zhang Y, Kulkarni A, Amarasinghe K, Li J, Vergara IA, Molania R, Papenfuss AT, McLean C, Shackleton M, Harvey KF. The Hippo pathway oncoprotein YAP promotes melanoma cell invasion and spontaneous metastasis. Oncogene. PMID 32561850 DOI: 10.1038/S41388-020-1362-9 |
0.786 |
|
| 2020 |
Zhang X, Yang L, Vergara I, Szeto P, Zhang Y, Papenfuss A, Shackleton M, Harvey K. Abstract IA03: The Hippo pathway in melanoma Molecular Cancer Research. 18. DOI: 10.1158/1557-3125.Hippo19-Ia03 |
0.486 |
|
| 2019 |
Samuel E, Moore M, Voskoboynik M, Shackleton M, Haydon A. An update on adjuvant systemic therapies in melanoma. Melanoma Management. 6: MMT28. PMID 31807279 DOI: 10.2217/Mmt-2019-0009 |
0.326 |
|
| 2019 |
Tan L, Sandhu S, Lee RJ, Li J, Callahan J, Ftouni S, Dhomen N, Middlehurst P, Wallace A, Raleigh J, Hatzimihalis A, Henderson MA, Shackleton M, Haydon A, Mar V, et al. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30838379 DOI: 10.1093/Annonc/Mdz048 |
0.321 |
|
| 2019 |
Zhang X, Tang JZ, Vergara IA, Zhang Y, Szeto P, Yang L, Mintoff C, Colebatch A, Mcintosh L, Mitchell KA, Shaw E, Rizos H, Long GV, Hayward N, McArthur GA, ... ... Shackleton M, et al. Somatic hypermutation of the YAP oncogene in a human cutaneous melanoma. Molecular Cancer Research : McR. PMID 30833299 DOI: 10.1158/1541-7786.Mcr-18-0407 |
0.772 |
|
| 2017 |
Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, Patch AM, Kakavand H, Alexandrov LB, Burke H, Jakrot V, Kazakoff S, Holmes O, Leonard C, Sabarinathan R, ... ... Shackleton M, et al. Whole-genome landscapes of major melanoma subtypes. Nature. PMID 28467829 DOI: 10.1038/Nature22071 |
0.358 |
|
| 2017 |
Noguchi F, Inui S, Fedele C, Shackleton M, Itami S. Calcium-Dependent Enhancement by Extracellular Acidity of the Cytotoxicity of Mitochondrial Inhibitors against Melanoma. Molecular Cancer Therapeutics. 16: 936-947. PMID 28223427 DOI: 10.1158/1535-7163.Mct-15-0235 |
0.778 |
|
| 2016 |
Eskiocak U, Ramesh V, Gill JG, Zhao Z, Yuan SW, Wang M, Vandergriff T, Shackleton M, Quintana E, Frankel AE, Johnson TM, DeBerardinis RJ, Morrison SJ. Erratum: Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma. Nature Communications. 7: 13080. PMID 27681157 DOI: 10.1038/ncomms13080 |
0.758 |
|
| 2016 |
Paul PJ, Raghu D, Chan AL, Gulati T, Lambeth L, Takano E, Herold MJ, Hagekyriakou J, Vessella RL, Fedele C, Shackleton M, Williams ED, Fox S, Williams S, Haupt S, et al. Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP. Oncogene. PMID 27641331 DOI: 10.1038/Onc.2016.159 |
0.78 |
|
| 2016 |
Alsop K, Thorne H, Sandhu S, Hamilton A, Mintoff C, Christie E, Spruyt O, Williams S, McNally O, Mileshkin L, Ananda S, Hallo J, Loi S, Scott C, Savas P, ... ... Shackleton M, et al. A community-based model of rapid autopsy in end-stage cancer patients. Nature Biotechnology. PMID 27617737 DOI: 10.1038/Nbt.3674 |
0.755 |
|
| 2016 |
Eskiocak U, Ramesh V, Gill JG, Zhao Z, Yuan SW, Wang M, Vandergriff T, Shackleton M, Quintana E, Johnson TM, DeBerardinis RJ, Morrison SJ. Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma. Nature Communications. 7: 12336. PMID 27545456 DOI: 10.1038/Ncomms12336 |
0.809 |
|
| 2016 |
Tan LY, Mintoff C, Johan MZ, Ebert BW, Fedele C, Zhang YF, Szeto P, Sheppard KE, McArthur GA, Foster-Smith E, Ruszkiewicz A, Brown MP, Bonder CS, Shackleton M, Ebert LM. Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome. Oncotarget. PMID 27340778 DOI: 10.18632/Oncotarget.10216 |
0.809 |
|
| 2016 |
Ebert LM, Tan LY, Johan MZ, Min KK, Cockshell MP, Parham KA, Betterman KL, Szeto P, Boyle S, Silva L, Peng A, Zhang Y, Ruszkiewicz A, Zannettino AC, Gronthos S, ... ... Shackleton M, et al. A non-canonical role for desmoglein-2 in endothelial cells: implications for neoangiogenesis. Angiogenesis. PMID 27338829 DOI: 10.1007/S10456-016-9520-Y |
0.771 |
|
| 2016 |
Boyle SE, Fedele CG, Corbin V, Wybacz E, Szeto P, Lewin J, Young RJ, Wong A, Fuller R, Spillane J, Speakman D, Donahoe S, Pohl M, Gyorki D, Henderson MA, ... ... Shackleton M, et al. CD271 Expression on Patient Melanoma Cells Is Unstable and Unlinked to Tumorigenicity. Cancer Research. PMID 27325642 DOI: 10.1158/0008-5472.Can-15-2377 |
0.723 |
|
| 2015 |
Wong SQ, Waldeck K, Vergara IA, Schröder J, Madore J, Wilmott JS, Colebatch AJ, De Paoli-Iseppi R, Li J, Lupat R, Semple T, Arnau GM, Fellowes A, Leonard JH, Hruby G, ... ... Shackleton M, et al. UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. Cancer Research. PMID 26627015 DOI: 10.1158/0008-5472.Can-15-1877 |
0.38 |
|
| 2015 |
Dewaele M, Tabaglio T, Willekens K, Bezzi M, Teo SX, Low DH, Koh CM, Rambow F, Fiers M, Rogiers A, Radaelli E, Al-Haddawi M, Tan SY, Hermans E, Amant F, ... ... Shackleton M, et al. Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth. The Journal of Clinical Investigation. PMID 26595814 DOI: 10.1172/Jci82534 |
0.452 |
|
| 2015 |
Wilmott JS, Field MA, Johansson PA, Kakavand H, Shang P, De Paoli-Iseppi R, Vilain RE, Pupo GM, Tembe V, Jakrot V, Shang CA, Cebon J, Shackleton M, Fitzgerald A, Thompson JF, et al. Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes. Pathology. PMID 26517638 DOI: 10.1097/Pat.0000000000000324 |
0.36 |
|
| 2015 |
Ramsdale R, Jorissen RN, Li FZ, Al-Obaidi S, Ward T, Sheppard KE, Bukczynska PE, Young RJ, Boyle SE, Shackleton M, Bollag G, Long GV, Tulchinsky E, Rizos H, Pearson RB, et al. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma. Science Signaling. 8: ra82. PMID 26286024 DOI: 10.1126/Scisignal.Aab1111 |
0.781 |
|
| 2015 |
He M, Lovell J, Ng BL, Spillane J, Speakman D, Henderson MA, Shackleton M, Gyorki DE. Post-operative survival following metastasectomy for patients receiving BRAF inhibitor therapy is associated with duration of pre-operative treatment and elective indication. Journal of Surgical Oncology. 111: 980-4. PMID 26080731 DOI: 10.1002/Jso.23938 |
0.355 |
|
| 2015 |
Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, ... ... Shackleton M, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 521: 489-94. PMID 26017449 DOI: 10.1038/Nature14410 |
0.356 |
|
| 2015 |
Puzanov I, Amaravadi RK, McArthur GA, Flaherty KT, Chapman PB, Sosman JA, Ribas A, Shackleton M, Hwu P, Chmielowski B, Nolop KB, Lin PS, Kim KB. Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. European Journal of Cancer (Oxford, England : 1990). 51: 1435-43. PMID 25980594 DOI: 10.1016/J.Ejca.2015.04.010 |
0.334 |
|
| 2015 |
Tang Jz, Zhang X, Vergara I, Papenfuss A, Harvey K, Shackleton M. Abstract B157: YAP is a promising target in cutaneous melanoma Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B157 |
0.394 |
|
| 2014 |
Gyorki DE, Spillane J, Speakman D, Shackleton M, Henderson MA. Current management of advanced melanoma: a transformed landscape. Anz Journal of Surgery. 84: 612-7. PMID 24842394 DOI: 10.1111/Ans.12673 |
0.338 |
|
| 2014 |
Schröder J, Hsu A, Boyle SE, Macintyre G, Cmero M, Tothill RW, Johnstone RW, Shackleton M, Papenfuss AT. Socrates: identification of genomic rearrangements in tumour genomes by re-aligning soft clipped reads. Bioinformatics (Oxford, England). PMID 24389656 DOI: 10.1093/Bioinformatics/Btt767 |
0.727 |
|
| 2013 |
Piskounova E, Quintana E, Shackleton M, Johnson TM, Morrison SJ. Abstract C9: Human melanoma metastasis in NSG mice correlates with clinical outcome in patients Cancer Research. 73. DOI: 10.1158/1538-7445.Tim2013-C9 |
0.807 |
|
| 2012 |
Quintana E, Piskounova E, Shackleton M, Weinberg D, Eskiocak U, Fullen DR, Johnson TM, Morrison SJ. Human melanoma metastasis in NSG mice correlates with clinical outcome in patients. Science Translational Medicine. 4: 159ra149. PMID 23136044 DOI: 10.1126/Scitranslmed.3004599 |
0.784 |
|
| 2012 |
Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele M, Villar S, Zwolinska A, Haupt S, de Lange J, Yip D, Goydos J, Haigh JJ, Haupt Y, Larue L, Jochemsen A, ... ... Shackleton M, et al. MDM4 is a key therapeutic target in cutaneous melanoma. Nature Medicine. 18: 1239-47. PMID 22820643 DOI: 10.1038/Nm.2863 |
0.782 |
|
| 2012 |
Tikoo A, Roh V, Montgomery KG, Ivetac I, Waring P, Pelzer R, Hare L, Shackleton M, Humbert P, Phillips WA. Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors. Plos One. 7: e36924. PMID 22666336 DOI: 10.1371/Journal.Pone.0036924 |
0.409 |
|
| 2011 |
Shackleton M. Pulling RANK: are some melanoma cells more malignant than others? The Journal of Investigative Dermatology. 131: 814-6. PMID 21407234 DOI: 10.1038/Jid.2011.18 |
0.449 |
|
| 2011 |
Carter CC, McNamara LA, Onafuwa-Nuga A, Shackleton M, Riddell J, Bixby D, Savona MR, Morrison SJ, Collins KL. HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells. Cell Host & Microbe. 9: 223-34. PMID 21402361 DOI: 10.1016/J.Chom.2011.02.005 |
0.609 |
|
| 2010 |
Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, Johnson TM, Morrison SJ. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell. 18: 510-23. PMID 21075313 DOI: 10.1016/J.Ccr.2010.10.012 |
0.807 |
|
| 2010 |
Shackleton M. Moving targets that drive cancer progression. The New England Journal of Medicine. 363: 885-6. PMID 20818851 DOI: 10.1056/Nejmcibr1006328 |
0.411 |
|
| 2010 |
Shackleton M. Melanoma stem cells--are there devils in the detail? Pigment Cell & Melanoma Research. 23: 693-4. PMID 20704685 DOI: 10.1111/J.1755-148X.2010.00750.X |
0.307 |
|
| 2010 |
Shackleton M, Quintana E. Progress in understanding melanoma propagation Molecular Oncology. 4: 451-457. PMID 20655286 DOI: 10.1016/J.Molonc.2010.06.006 |
0.774 |
|
| 2010 |
Shackleton M. Normal stem cells and cancer stem cells: similar and different. Seminars in Cancer Biology. 20: 85-92. PMID 20435143 DOI: 10.1016/J.Semcancer.2010.04.002 |
0.41 |
|
| 2010 |
Quintana E, Shackleton M, Morrison SJ. Abstract PL03-02: Some cancers follow a stem cell model, while other cancers have common tumorigenic cells with little hierarchical organization Tumor Biology. DOI: 10.1158/1538-7445.Am10-Pl03-02 |
0.764 |
|
| 2009 |
Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell. 138: 822-9. PMID 19737509 DOI: 10.1016/J.Cell.2009.08.017 |
0.757 |
|
| 2009 |
Shackleton M, O'Reilly LA, Sutherland KD, Bath ML, Ellis S, Strasser A, Visvader JE, Lindeman GJ. Impaired lactation in mice expressing dominant-negative FADD in mammary epithelium. Developmental Dynamics : An Official Publication of the American Association of Anatomists. 238: 1010-6. PMID 19301394 DOI: 10.1002/Dvdy.21917 |
0.401 |
|
| 2009 |
Johnson TM, Shackleton MJ, Quintana E, Fullen DR, Sabel MS. Melanoma: Do we need a hatchet or a scalpel? Archives of Dermatology. 145: 307-308. PMID 19289763 DOI: 10.1001/Archdermatol.2009.3 |
0.703 |
|
| 2008 |
Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature. 456: 593-8. PMID 19052619 DOI: 10.1038/Nature07567 |
0.798 |
|
| 2008 |
Asselin-Labat ML, Vaillant F, Shackleton M, Bouras T, Lindeman GJ, Visvader JE. Delineating the epithelial hierarchy in the mouse mammary gland. Cold Spring Harbor Symposia On Quantitative Biology. 73: 469-78. PMID 19022771 DOI: 10.1101/Sqb.2008.73.020 |
0.399 |
|
| 2008 |
Vaillant F, Asselin-Labat ML, Shackleton M, Forrest NC, Lindeman GJ, Visvader JE. The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Research. 68: 7711-7. PMID 18829523 DOI: 10.1158/0008-5472.Can-08-1949 |
0.437 |
|
| 2007 |
Vaillant F, Asselin-Labat ML, Shackleton M, Lindeman GJ, Visvader JE. The emerging picture of the mouse mammary stem cell. Stem Cell Reviews. 3: 114-23. PMID 17873344 DOI: 10.1007/S12015-007-0018-2 |
0.358 |
|
| 2007 |
Asselin-Labat ML, Sutherland KD, Barker H, Thomas R, Shackleton M, Forrest NC, Hartley L, Robb L, Grosveld FG, van der Wees J, Lindeman GJ, Visvader JE. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nature Cell Biology. 9: 201-9. PMID 17187062 DOI: 10.1038/Ncb1530 |
0.344 |
|
| 2006 |
Asselin-Labat ML, Shackleton M, Stingl J, Vaillant F, Forrest NC, Eaves CJ, Visvader JE, Lindeman GJ. Steroid hormone receptor status of mouse mammary stem cells. Journal of the National Cancer Institute. 98: 1011-4. PMID 16849684 DOI: 10.1093/Jnci/Djj267 |
0.382 |
|
| 2006 |
Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, Wu L, Lindeman GJ, Visvader JE. Generation of a functional mammary gland from a single stem cell. Nature. 439: 84-8. PMID 16397499 DOI: 10.1038/Nature04372 |
0.356 |
|
| 2006 |
Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, Li HI, Eaves CJ. Purification and unique properties of mammary epithelial stem cells. Nature. 439: 993-7. PMID 16395311 DOI: 10.1038/Nature04496 |
0.366 |
|
| 2005 |
Sum EY, Shackleton M, Hahm K, Thomas RM, O'Reilly LA, Wagner KU, Lindeman GJ, Visvader JE. Loss of the LIM domain protein Lmo4 in the mammary gland during pregnancy impedes lobuloalveolar development. Oncogene. 24: 4820-8. PMID 15856027 DOI: 10.1038/Sj.Onc.1208638 |
0.355 |
|
| 2005 |
Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, Chen Q, Dimopoulos N, Luke T, Murphy R, Scott AM, Maraskovsky E, McArthur G, MacGregor D, Sturrock S, et al. Erratum: Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans (Proceedings of the National Academy of Sciences of the United States of America (July 20, 2004) 101, 29 (10697-10702)) Proceedings of the National Academy of Sciences of the United States of America. 102. DOI: 10.1073/Pnas.0504548102 |
0.314 |
|
| 2004 |
Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, Chen Q, Dimopoulos N, Luke T, Murphy R, Scott AM, Maraskovsky E, McArthur G, MacGregor D, Sturrock S, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proceedings of the National Academy of Sciences of the United States of America. 101: 10697-702. PMID 15252201 DOI: 10.1073/Pnas.0403572101 |
0.323 |
|
| Show low-probability matches. |